Previous studies suggested that the location of the primary tumor in non-small cell lung cancer (NSCLC) is associated with clinical features and prognosis, but results are conflicting. The purpose of this study was to explore tumor location as an independent risk factor of survival for patients with completely resected pathological stage I NSCLC. This was a multicenter retrospective study conducted in Taiwan. Included patients were diagnosed with stage I NSCLC and had undergone primary tumor resection. Variables including tumor location, pathological stage, histological differentiation, and International Association for the Study of Lung Cancer (IASLC) grade were evaluated for predictive ability for disease-free survival (DFS) and overall survival (OS). A total of 208 patients were included, with 123 (59.1%) patients having a primary tumor in the upper and middle lobes. The median duration of follow-up for survivors was 60.5 months. Compared to patients with IASLC Grade 3 disease, patients with Grade 1 disease had significantly longer DFS. Tumor location and IASLC grade were independent predictors for OS in multivariate analysis. Specifically, patients with NSCLC in the lower lobe and patients who are histologically classified as IASLC Grade 3 may have poorer prognosis and require greater attention to improve outcomes.
既往研究表明，非小细胞肺癌（NSCLC）原发肿瘤的位置与临床特征及预后相关，但研究结果存在矛盾。本研究旨在探讨肿瘤位置作为完全切除的病理Ⅰ期NSCLC患者生存独立危险因素的作用。本研究为在台湾开展的多中心回顾性研究。纳入患者均诊断为Ⅰ期NSCLC并接受原发肿瘤切除术。研究评估了包括肿瘤位置、病理分期、组织学分化程度及国际肺癌研究协会（IASLC）分级在内的变量对无病生存期（DFS）和总生存期（OS）的预测能力。共纳入208例患者，其中123例（59.1%）患者的原发肿瘤位于上叶和中叶。幸存者的中位随访时间为60.5个月。与IASLC 3级患者相比，1级患者的DFS显著更长。多变量分析显示，肿瘤位置和IASLC分级是OS的独立预测因素。具体而言，下叶NSCLC患者及组织学分类为IASLC 3级的患者可能预后较差，需给予更多关注以改善临床结局。
肿瘤(癌症)患者之家